A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Veracyte, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 40,873 shares of VCYT stock, worth $1.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
40,873
Previous 38,884 5.12%
Holding current value
$1.6 Million
Previous $842,000 65.08%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.0 - $35.25 $41,769 - $70,112
1,989 Added 5.12%
40,873 $1.39 Million
Q2 2024

Aug 14, 2024

BUY
$18.86 - $23.55 $733,352 - $915,718
38,884 New
38,884 $842,000
Q2 2023

Aug 14, 2023

SELL
$20.96 - $26.99 $38,377 - $49,418
-1,831 Reduced 5.12%
33,950 $864,000
Q1 2023

May 15, 2023

BUY
$20.58 - $27.89 $736,372 - $997,932
35,781 New
35,781 $798,000
Q3 2022

Nov 14, 2022

BUY
$16.58 - $27.9 $513,416 - $863,951
30,966 New
30,966 $514,000
Q2 2022

Aug 15, 2022

SELL
$15.45 - $29.52 $372,097 - $710,959
-24,084 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$21.94 - $42.51 $97,567 - $189,041
4,447 Added 22.65%
24,084 $664,000
Q4 2021

Feb 14, 2022

BUY
$36.09 - $53.79 $708,699 - $1.06 Million
19,637 New
19,637 $809,000
Q3 2021

Nov 15, 2021

SELL
$35.62 - $52.97 $685,649 - $1.02 Million
-19,249 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$32.94 - $56.62 $472,326 - $811,874
14,339 Added 292.04%
19,249 $770,000
Q1 2021

May 17, 2021

SELL
$44.47 - $81.38 $931,690 - $1.7 Million
-20,951 Reduced 81.01%
4,910 $264,000
Q4 2020

Feb 16, 2021

BUY
$32.49 - $61.88 $840,223 - $1.6 Million
25,861 New
25,861 $1.27 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.8B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.